IRIDEX Corporation (IRIX)
IRIX Price and Sentiment
IRIX Latest news
IRIDEX Corporation (IRIX) CEO Dave Bruce on Q3 2021 Results - Earnings Call Transcript
Achieved 51% Year-over-Year Revenue Growth and Raises 2021 Revenue Guidance Achieved 51% Year-over-Year Revenue Growth and Raises 2021 Revenue Guidance
Iridex (IRIX) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher in the near term.
Retina and Glaucoma Experts Will Present Best Practices Using Iridex Technologies at a Consensus Panel and the AAO Annual Meeting2021-11-06 12:44
An international expert consensus panel will discuss best practices in dosing and patient selection using MicroPulse TLT on November 6, 2021
Iridex (IRIX) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Micro-cap stocks offer big growth potential, but not all opportunities are created equal. Each of these earns a Portfolio Grader “A” rating.
MOUNTAIN VIEW, Calif., Oct. 28, 2021 (GLOBE NEWSWIRE) -- Iridex Corporation (NASDAQ: IRIX), a provider of innovative ophthalmic laser-based medical products for the treatment of glaucoma and retinal diseases, today announced the Company will release financial results for the third quarter of 2021 after the close of trading on Thursday, November 11, 2021. The Company's management team will host a corresponding conference call beginning at 2:00 p.m. PT / 5:00 p.m. ET.
IRIDEX (IRIX) has seen solid earnings estimate revision activity over the past month, and belongs to a strong industry as well.
Iridex Corporation (NASDAQ: IRIX) reported Q2 revenue of $13.4 million, the highest since 2007, +116% Y/Y, beating the consensus of $11.61 million. Cyclo G6 product family generated sales of $3.6 million, +70% Y/Y on 16,000 probes sold, up 103% Y/Y.
IRIDEX Corporation (IRIX) CEO Dave Bruce on Q2 2021 Results - Earnings Call Transcript